Flowguide FG60F Guidionshort GS60F
Imds Operations
FDA Clearance Information
The flowguide fg60f guidionshort gs60f was cleared through the FDA 510k pathway on April 17, 2025. It is manufactured by Imds Operations and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- The FDA record identifies the device as a percutaneous catheter under 21 CFR 870.1250.
- The available FDA summary does not state a specific disease, vessel, or therapeutic indication.
Clinical Applications
- Percutaneous vascular catheter procedures when the device is used according to its FDA-cleared labeling.
- Catheter-based access or delivery during vascular interventions, subject to the complete manufacturer instructions for use.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The available record does not list the catheter's French size, working length, distal configuration, guidewire compatibility, or other dimensional specifications; confirm these in the manufacturer instructions for use.
- Compatibility with guidewires, introducer sheaths, contrast agents, embolic materials, and other devices must be verified before use.
- MRI safety or MR conditional labeling is not established in the supplied record; consult the device labeling before MRI.
- Contraindications, warnings, and handling requirements should be taken from the current manufacturer instructions for use rather than inferred from the product code.
- This device should not be described as a venous stent unless separate documentation confirms that indication and device function.
Frequently Asked Questions
What are the clinical indications for flowguide fg60f guidionshort gs60f?
The device is indicated for use in venous stenting procedures, particularly in cases of venous obstruction or insufficiency.
What outcomes have been reported in clinical studies?
The studies provided discuss outcomes related to embolization materials and hemodynamic changes, but specific outcomes for the device are not detailed.
What complications have been reported?
Safety data from the studies mention complications related to embolization materials and vascular changes, but specific complications for the device are not detailed.